重组人白介素-11联合生血宝合剂治疗乳腺癌药源性血小板减少症的效果  

Effect of Recombinant Human Interleukin-11 Combined with Shengxuebao Mixture in the Treatment of Drug-induced Thrombocytopenia of Breast Cancer

作　　者：叶华斌 陈凯旋 刘吉梅 叶永强 陈露文 叶颖 刘地林 YE Huabin;CHEN Kaixuan;LIU Jimei;YE Yongqiang;CHEN Luwen;YE Ying;LIU Dilin(Department of Thoracic Surgery,Ganzhou Cancer Hospital,Ganzhou 341000,China;不详)

机构地区：[1]赣州市肿瘤医院胸外科,江西赣州341000

出　　处：《中国医学创新》2024年第26期58-61,共4页Medical Innovation of China

基　　金：赣州市卫生健康委员会科研项目(2020-2-44)。

摘　　要：目的:探讨重组人白介素-11联合生血宝合剂治疗乳腺癌药源性血小板减少症的效果。方法:选取2021年10月—2023年10月赣州市肿瘤医院收治的60例乳腺癌患者,以随机数字表法分为对照组、观察组,各30例。两组患者均接受恩美曲妥珠单抗治疗,对照组给予重组人白介素-11,观察组给予重组人白介素-11联合生血宝合剂。对比两组临床疗效、中医症候、血小板相关指标、治疗安全性。结果:观察组总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组中医症候积分均低于对照组,差异均有统计学意义(P<0.05)。治疗后,观察组血小板相关指标均高于对照组,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:重组人白介素-11与生血宝合剂联合治疗乳腺癌药源性血小板减少症的效果良好,可改善患者中医症候,提高血小板计数水平,治疗安全性良好。Objective:To investigate the effect of Recombinant Human Interleukin-11 combined with Shengxuebao Mixture in the treatment of drug-induced thrombocytopenia of breast cancer.Method:A total of 60 patients with breast cancer admitted to Ganzhou Cancer Hospital from October 2021 to October 2023 were selected and divided into control group and observation group by random number table method,with 30 cases in each group.The patients in both groups were treated with Trastuzumab Emtansine,the control group was given Recombinant Human Interleukin-11,and the observation group was given Recombinant Human Interleukin-11 combined with Shengxuebao Mixture.The clinical efficacy,TCM symptoms,platelet-related indexes and therapeutic safety of the two groups were compared.Result:The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).After treatment,the scores of TCM symptoms in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,the platelet-related indexes in the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combination of Recombinant Human Interleukin-11 and Shengxuebao Mixture has a good effect in the treatment of drug-induced thrombocytopenia of breast cancer,which can improve TCM symptoms of patients,improve the level of platelet count and have good treatment safety.

关 键 词：乳腺癌 恩美曲妥珠单抗 血小板减少症 重组人白介素-11 生血宝合剂 

分 类 号：R737.9[医药卫生—肿瘤]